• 1
    Arii S, Okamoto E, Imamura M. Registries in Japan: current status of hepatocellular carcinoma in Japan-Liver Cancer Study Group of Japan. Semin Surg Oncol. 1996; 12: 204211.
  • 2
    Soulen M. Chemoembolization of hepatic malignancies. Oncology. 1994; 8: 7784.
  • 3
    Solomon B, Soulen M, Baum R, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. J Vasc Interv Radiol. 1999; 10: 793798.
  • 4
    Farmer DG, Resove MH, Shaked A, Busuttil RW. Current treatment modalities for hepatocellular carcinoma. Ann Surg. 1994; 219: 236247.
  • 5
    Okuda K, Obata H, Nakajima Y, et al. Prognosis of hepatocellular carcinoma. Hepatology. 1984; 4(Suppl): S36.
  • 6
    Ngan H, Lai C, Fan S, et al. Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four year follow up. J Vasc Interv Radiol. 1996; 7: 419425.
  • 7
    Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983; 148: 397401.
  • 8
    Kakamura H, Mitani T, Murakami T, et al. Five year survival after transcatheter chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol. 1994; 33(Suppl): S89S92.
  • 9
    Barbara L, Benzi G, Giani S, et al. Natural history of small untreated carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992; 16: 132137.
  • 10
    Farinati F, De Maria N, Marafin C, et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci. 1996; 41: 23322339.
  • 11
    Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, Carr BI. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR. 2000; 175: 16651672.
  • 12
    Bengmark S, Hafstorm L. The natural history of primary and secondary malignant tumors of the liver. Cancer. 1969; 23: 198202.
  • 13
    Cady B, Stone MD. The role of surgical resection of liver metastasis in colorectal carcinoma. Semin Oncol. 1991; 18: 399406.
  • 14
    Satho M, Yamada R. Experimental and clinical studies on the hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983; 148: 397401.
  • 15
    Bayraktar Y, Balkanci F, Kayhan B, et al. A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma. Hepatogastroenterology. 1996; 43: 681687.
  • 16
    Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR. 2000; 175: 699704.
  • 17
    Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in western hepatocellular carcinoma: a prospective study of 224 patients. Hepatology. 1998; 29: 650659.
  • 18
    Santis MD, Torricelli P, Cristani A, et al. MRI of hepatocellular carcinoma before and after transcatheter chemoembolization. J Comput Assist Tomogr. 1993; 17: 901908.
  • 19
    Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on survival time in patients with hepatocellular carcinoma. Cancer. 1991; 68: 21502154.
  • 20
    Cioni D, Lencioni R, Bartolozzi C. Therapeutic effect of transcatheter arterial chemoembolization on hepatocellular carcinoma: evaluation with contrast-enhanced harmonic power Doppler ultrasound. Eur Radiol. 2000; 10: 15701575.
  • 21
    Mandazzi L, Botelli R, Brambilla G, et al. Transcatheter oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994; 19: 11171123.
  • 22
    Vogl T, Trapp M, Schroeder H, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success — results from a liver transplantation center. Radiology. 2000; 214: 349357.
  • 23
    Yamashita Y, Takahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer. 1991; 67: 385391.
  • 24
    Carr BI, Selby R, Madariaga J, et al. A controlled, prospective randomized trial comparing intra-arterial cisplatin and doxorubicin with or without lipiodol for hepatocellular carcinoma. Hepatology. 1992; 16: 60.